Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES - Wikidata - thesis-toulmin - TriplyDB

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

http://www.wikidata.org/entity/Q34823587

about

Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Closing the door to human immunodeficiency virus.Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry."Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5 Highly potent chimeric inhibitors targeting two steps of HIV cell entry Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies.Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells.Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120 Multiple roles for chemokines in the pathogenesis of SIV infection Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.CCR5 antagonists: the answer to inflammatory disease?Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.G protein coupled receptors as allosteric proteins and the role of allosteric modulators.Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function Specific microbicides in the prevention of HIV infection.HIV-1 Entry, Inhibitors, and Resistance Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES.Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5 Evolution of CCR5 use before and during coreceptor switching Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis.

P2860

Q24620129-9890A715-DF67-4A6B-80E3-996EBEBFA967 Q27657257-5A110B87-85F1-48C2-A27F-5F475AB558C1 Q28743199-831C8F11-D421-4803-9508-017FFE0B9BCC Q30428089-D372DCEE-328D-48CA-9457-76FE1B8796A3 Q33846502-0666CD08-C9A5-4150-B7CD-DB0B073147AC Q33877312-49045C88-49F5-4C43-91C0-C0A0AE9A8ED7 Q33961704-8FB7AE9C-9773-4E39-9E3B-7DC1FF5F1293 Q34282386-2550C1AF-8952-4BC3-93E2-F8E6054EECCA Q34438951-83D5BE5B-DD67-448B-AA02-4A0FA4B82360 Q34568280-5B82A129-5309-4EFE-BBBC-A98053791B50 Q35122309-544F0BC6-5D04-4526-A4CE-F82F516E8168 Q35122466-70260CAE-0FD1-4CBA-802B-D999F57B3413 Q35140944-EDC93031-4B6B-4BCC-9D63-9344632A63BB Q35150195-CA92A253-FF2D-4260-9539-7EF3A2165162 Q35528569-F946D30D-EDC4-4409-BD87-212085E9D346 Q35785164-0706FDEC-00A6-4EEF-A27A-3C8C2B0ADD27 Q35947621-E4519855-968A-47E7-987D-5C7B3E8E7298 Q36028163-B16EF1C4-6B8C-4738-8B03-9D4DA8B3AE2B Q36528775-53FBFC07-BBC5-4A79-B028-2D11C130A314 Q36559608-0D636679-6327-4B4E-8867-77717A78AD5B Q36634172-57B7A439-C6D6-417B-8138-C68A1EB80CE3 Q36976659-25255EFE-E0C4-41FD-B86C-C4F5B74AD289 Q37026646-4627E2C8-2C09-43DE-A8D6-298F1277DC83 Q37192119-C932BF62-7C17-4242-A511-1FE502D11035 Q37356028-70150647-2323-4EA1-8B77-33DD93C62EB2 Q37689783-1742A21F-EB08-41F4-86C8-5D20548BBAD4 Q37692401-15B914DB-D53B-452A-8A9F-56360DAD05A5 Q37790693-FB5FF9E7-D5A4-4F58-B699-7ED3DEBD3926 Q37827607-8A578044-7E0A-4554-83D1-575AA1869161 Q37932048-E1713890-3CB4-4432-8A88-24B9DF1154A6 Q37945205-2071B19F-64AF-4516-A105-05A233C4F0E1 Q38076139-76FE12D5-D88D-45F9-BF77-A25DA3E386AE Q39186710-71BB40C7-7743-46EB-B67E-03253B3E592D Q40115327-7891FA6A-A349-48EA-BF4C-0102D8D52532 Q41897622-755E667C-EDE4-4207-A5DF-4C524224FAD0 Q41995185-6809D4D2-D984-4B5F-933D-72436E83C4F2 Q42348438-2FC7BB48-D148-424A-A705-AD9B7B4EBE22 Q42406917-BC20F928-5284-47CB-BCE9-805B0583423B Q45423213-4AE7E77B-7DD0-4308-A622-8678C9AFC60F

P2860

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

http://www.wikidata.org/entity/Q34823587

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Two mechanisms for human immun ...... rminal modifications of RANTES

@ast

Two mechanisms for human immun ...... rminal modifications of RANTES

@en

Two mechanisms for human immun ...... rminal modifications of RANTES

@nl

type

label

Two mechanisms for human immun ...... rminal modifications of RANTES

@ast

Two mechanisms for human immun ...... rminal modifications of RANTES

@en

Two mechanisms for human immun ...... rminal modifications of RANTES

@nl

prefLabel

Two mechanisms for human immun ...... rminal modifications of RANTES

@ast

Two mechanisms for human immun ...... rminal modifications of RANTES

@en

Two mechanisms for human immun ...... rminal modifications of RANTES

@nl

P1433

Q34823587-5D80B52C-B098-482F-A854-42D1E2810725

P1476

Q34823587-59576877-323D-4296-BF85-1DFDCD14D517

P2093

Q34823587-224FBE09-8F0C-480E-9F4F-23D9C16A22B7

Q34823587-4A89FD27-04A3-48F3-A6D6-CC6E477A90C2

Q34823587-6C0B46E8-6DA8-4571-83A9-A1FA8007E953

Q34823587-72229895-5136-4DA7-B608-9741304BC898

Q34823587-C9523371-EA51-4573-9180-92D6E815638C

Q34823587-D1F90558-BBD5-4A0F-A7A9-DAEF057A12AB

Q34823587-D72FECA6-B71E-4856-8944-04E6410E36E2

P2860

Q34823587-04A47583-B799-4834-B409-36C7A84725D0

Q34823587-0725EE3D-6834-4E0A-89B4-7EF97F3FEF14

Q34823587-087F593C-0B21-49C5-A791-BFECA2867537

Q34823587-0C3BA386-EFDB-4151-9457-908825C6E18E

Q34823587-14F87194-4C98-43EA-B969-90BE5D472470

Q34823587-19402D79-4640-4095-9A62-8F1798D1B60C

Q34823587-19C52DD1-BF05-4CA2-B07C-32E3920B4AA4

Q34823587-1F52B358-FD99-4212-81CA-251E500AD857

Q34823587-25F9EE42-F2A5-49F1-B11D-4D328BEBBF95

Q34823587-2C9CFA81-C066-4FB0-AF17-31016481E13B

P304

Q34823587-E5709173-1D1C-4420-8465-BBC767F1EEE1

P31

Q34823587-158A77E3-92C8-4A85-825E-AC729A6A76B4

P356

Q34823587-2CB57538-C194-4428-99D4-DAB4788C5F9A

P407

Q34823587-1CC53260-B716-4AAF-B8AA-F77D3A413F96

P433

Q34823587-85DAC11F-2827-44C2-A26F-6BDD0E1AE34A

P478

Q34823587-AD02F3C9-C5A0-475E-8303-EEB8B0AF3602

P577

Q34823587-F9BD5C97-DD2A-4D4E-A148-488A2F510EB2

P698

Q34823587-52561DF7-1433-4ADB-9457-4467DF1CDDC4

P932

Q34823587-60F6245B-FA63-48FE-B0D7-FA7C625A37DC

P356

AAC.47.2.509-517.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Two mechanisms for human immun ...... rminal modifications of RANTES

@en

P2093

Cristina Pastore

http://www.w3.org/2001/XMLSchema#string

Donald E Mosier

http://www.w3.org/2001/XMLSchema#string

Francesco Galimi

http://www.w3.org/2001/XMLSchema#string

Gastón R Picchio

http://www.w3.org/2001/XMLSchema#string

Oliver Hartley

http://www.w3.org/2001/XMLSchema#string

Richard Fish

http://www.w3.org/2001/XMLSchema#string

Robin E Offord

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

Identification of a major co-receptor for primary isolates of HIV-1

Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES

CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist

Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

A third-generation lentivirus vector with a conditional packaging system

P304

509-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.2.509-517.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12543651

http://www.w3.org/2001/XMLSchema#string

P932

151767

http://www.w3.org/2001/XMLSchema#string